Press Releases
July 9, 2008
FDA Grants Epeius Biotechnologies’ Rexin-G A Third Orphan Drug Designation, This Time For The Treatment Of Soft Tissue Sarcomas
July 9, 2008 PDF Version
July 8, 2008
Epeius Biotechnologies’ Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation For The Treatment Of Osteosarcoma
July 8, 2008 PDF Version
May 29, 2008
Phase I/Ii Study Of Targeted Gene Delivery In Vivo—Intravenous Infusions Of Rexin-G—Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity In Patients With Progressive Chemo-Resistant Bone And Soft Tissue Sarcoma (Asco 2008)
May 22, 2008 PDF Version
May 27, 2008
TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G followed by Reximmune-C induce tumor necrosis and recruitment of tumor infiltrating lymphocytes in cancerous lesions (ASCO 2008)
May 27, 2008 PDF Version
May 22, 2008
Targeted Gene Delivery In Vivo: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity In Chemo-Resistant Metastatic Breast Cancer (Asco 2008)
May 22, 2008 PDF Version
May 19, 2008
Asco 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity In Metastatic Pancreatic Cancer May 19, 2008 PDF Version
April 21, 2008
Interim Analysis Of Phase I/Ii Study Of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity In Metastatic Pancreatic Cancer; Second Phase Opens With Higher Dose Regimens April 21, 2008 PDF Version
March 25, 2008
Epeius Biotechnologies awarded U.S. patent for targeted injectable gene delivery in vivo March 25, 2008 PDF Version
December 18, 2007
ASEAN News: Epeius Biotechnologies Gains Commercial Approval For Rexin-G®, A Tumor-Targeted Gene-Based Medicine For Metastatic Cancer December 18, 2007 PDF Version
November 5, 2007
FDA Approves The Opening Of A Phase II Registration Protocol Using Rexin-G® For Osteosarcoma In California U.S.A. November 5, 2007 PDF Version
July 10, 2007
California Biotechnology Company Takes Aim At Pancreatic Cancer With An Advanced Phase I/Ii Clinical Trial Using Rexin-G™, A Targeted Injectable Gene Delivery System July 10, 2007 PDF Version
June 4, 2007
Epeius Biotechnologies Reaches Out To American Cancer Patients, Gains FDA Approval For Two New Clinical Trials Using Rexin-G (Tm) For Breast Cancer And Sarcoma June 4, 2007 PDF Version
June 4, 2007
News From The Battlefield Of Metastatic Cancer: Epeius Biotechnologies Draws The Sword Of Targeted Gene Delivery (Rexin-G) From The Stone Of Chemistry And Physics June 4, 2007 PDF Version
You must have Adobe Acrobat Reader to view PDF files. You may download it for free by clicking here.